Table 6 Performance of abnormal biomarkers in low risk
From: A new contingent screening strategy increased detection rate of trisomy 21 in the first trimester
Risk stratification (risk < 1/1000) | Serum biochemical screening | Combined first-trimester screening | |||
|---|---|---|---|---|---|
n(%) | Trisomy 21 (%) | n(%) | Trisomy 21 (%) | ||
free β-hCG MoM ≥ 2.75 PAPP-A MoM ≤ 0.5 | 2,194 (7.72%) | 5 (55.56%) | 4,005 (12.36%) | 6 (85.71%) | |
free β-hCG MoM < 2.75 PAPP-A MoM > 0.5 | 26,211 (92.28%) | 4 (44.44%) | 28,398 (87.64%) | 1 (14.29%) | |